Autologous chondrocytes

Therapeutic indications

Autologous chondrocytes is indicated for:

Articular cartilage defect

Population group: only adults (18 - 65 years old)

Repair of symptomatic articular cartilage defects of the femoral condyle and the patella of the knee (International Cartilage Regeneration & Joint Preservation Society [ICRS] grade III or IV) with defect sizes up to 10 cm² in adults and adolescents with closed epiphyseal growth plate in the affected joint.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Autologous chondrocytes is contraindicated in the following cases:

Not fully closed epiphyseal growth plate in the affected joint

Delayed epiphyseal closure

Advanced osteoarthritis, primary (generalised) osteoarthritis

Osteoarthritis

Hepatitits B (HBV), hepatitis C (HCV), HIV I/II

at least one of
Type B viral hepatitis
Viral hepatitis C
Human immunodeficiency virus I infection
Human immunodeficiency virus II infection

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2021: SPHEROX Implantation suspension
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈